Among the changes currently being clinically investigated and recommended by ESMO for testing in advanced CCA are IDH1 mutations, FGFR2 and NTRK fusions, microsatellite instability, HER2, BRAF, and BRCA1/2 mutations. This evidence concerns the gene IDH1 and cholangiocarcinoma.